Fenoprofen in rheumatoid arthritis: a controlled crossover multi-centre study.
The pooled data of a multi-clinic, double-blind, crossover study (16 weeks' duration), comparing fenoprofen and aspirin in 116 patients with active rheumatoid arthritis are reported. Each patient received fenoprofen (400 mg Q6H) and aspirin (1,000 mg Q6H) for six-week periods, in random fashion. Usual objective and subjective parameters were used to evaluate rheumatic activity. Side effects were obtained by daily telephone interviews, and appropriate laboratory tests were performed during weekly out-patient evaluations. Both fenoprofen and aspirin were significantly more effective than placebo in controlling rheumatoid activity. At the dosage level employed, no significant differences were noted between the two anti-inflammatory agents in regard to efficacy. However, fewer side effects were observed with fenoprofen than with aspirin. The data indicate that fenoprofen is an additional valuable agent for rheumatoid arthritis.
D000293:Adolescent; D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D005279:Fenoprofen / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010666:Phenylpropionates / Q000627:therapeutic use*
D010666:Phenylpropionates; D001241:Aspirin; D005279:Fenoprofen